Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT GALMED PHARMACEUTICALS LTD.

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD)
Listen to this Section


$0.72
-0.0121 ( -1.66% ) 89.3K

Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.

Market Data


Open $0.72
Previous Close $0.73
Volume 89.3K
Market Cap $4.49M
Day Range $0.69 - $0.73
52 Week Range $0.41 - $2.34
Shares Outstanding 6.60M
Change % -1.66%
Net Change ▼ -0.0121
Insider Ownership N/A
Exchange NASDAQ
SectorHealthcare
IndustryBiotechnology: Pharmaceutical Preparations
IPO Year2014
CountryIsrael
UnderwriterIPO Intelligence Only

Insider Ownership Transactions

Total Amount Purchased: 0.00

Date Type Amount Purchased Purchaser
No records found.

SEC Filings


Form Type Description Pages Date
schedule Other 1 Nov 07, 2025
6-k Form 6-K 1 Oct 29, 2025
6-k Form 6-K 1 Oct 28, 2025
6-k Form 6-K 4 Sep 19, 2025
6-k Form 6-K 30 Aug 28, 2025
6-k Form 6-K 3 Aug 25, 2025
6-k Form 6-K 2 Aug 15, 2025
6-k Form 6-K 1 Aug 14, 2025
6-k Form 6-K 5 Jul 24, 2025

Latest News


× Before browsing our site, please accept our cookies policy